Denne siden ble automatisk oversatt og nøyaktigheten av oversettelsen er ikke garantert. Vennligst referer til engelsk versjon for en kildetekst.

En studie som evaluerer sikkerheten og effekten av kombinasjoner av flere behandlinger hos deltakere med myelomatose (PLYCOM)

4. november 2026 oppdatert av: Hoffmann-La Roche

En plattformstudie som evaluerer sikkerheten og effekten av kombinasjoner av flere behandlinger hos pasienter med myelomatose

CO43923 is a platform study that will evaluate the safety, efficacy, and pharmacokinetics (PK) of multiple treatment combinations, as monotherapy or in combination, in participants with multiple myeloma (MM). The study is designed with the flexibility to open new treatment substudies as new treatments become available. Information regarding the opened substudies are found below.

Studieoversikt

Detaljert beskrivelse

Cevos + Len substudy(SS) 2 (DIRAC):

This substudy will explore the combination of cevostamab and lenalidomide as post-transplant maintenance therapy in participants with MM with high-risk cytogenetic features who experienced at least a partial response (PR) after induction.

Cevostamab + Iberdomide SS4 (CHAWLA):

This substudy will evaluate the safety, tolerability, PK, and pharmacodynamics of the combination of cevostamab and iberdomide in participants with R/R MM who have received at least three prior lines of therapy, including a PI, an IMiD, and an anti-CD38 monoclonal antibody.

Studietype

Intervensjonell

Registrering (Antatt)

200

Fase

  • Fase 2
  • Fase 1

Kontakter og plasseringer

Denne delen inneholder kontaktinformasjon for de som utfører studien, og informasjon om hvor denne studien blir utført.

Studiekontakt

  • Navn: Fastest response: use the inquiry form. https://www.gene.com/contact-us/submit-medical-inquiry

Studer Kontakt Backup

  • Navn: Reference Study ID Number: CO43923 https://forpatients.roche.com/ No attachments to email below.
  • Telefonnummer: 888-662-6728 (U.S. and Canada)
  • E-post: global-roche-genentech-trials@gene.com

Studiesteder

    • New South Wales
      • Randwick, New South Wales, Australia, 2031
        • Rekruttering
        • Prince of Wales Hospital
    • Victoria
      • Fitzroy, Victoria, Australia, 3065
        • Rekruttering
        • St Vincent's Hospital Melbourne
      • Pierre-Bénite, Frankrike, 69310
        • Rekruttering
        • CHU Lyon Sud - Service Hématologie
      • Toulouse, Frankrike, 31059
        • Rekruttering
        • IUCT Oncopole
      • Tours, Frankrike, 37044
        • Rekruttering
        • Hopital Bretonneau
      • Villejuif, Frankrike, 94800
        • Tilbaketrukket
        • IGR
      • Gda?sk, Polen, 80-214
        • Rekruttering
        • Uniwersyteckie Centrum Kliniczne
      • Olsztyn, Polen, 10-228
        • Rekruttering
        • Szpital Kliniczny Ministerstwa Spraw Wewnetrznych i Administracji z Warminsko-Mazurskim Centrum Onkologii w Olsztynie
      • Późna, Polen, 60-569
        • Tilbaketrukket
        • Uniwersytecki Szpital Kliniczny w Poznaniu
      • Madrid, Spania, 28040
        • Rekruttering
        • Fundacion Jimenez Diaz
      • Valencia, Spania, 46010
        • Rekruttering
        • Hospital Clinico Universitario de Valencia
    • Barcelona
      • Badalona, Barcelona, Spania, 08915
        • Rekruttering
        • Hospital Universitari Germans Trias i Pujol
      • Seoul, Sør -Korea, 03722
        • Rekruttering
        • Severance Hospital, Yonsei University Health System
      • Seoul, Sør -Korea, 06351
        • Rekruttering
        • Samsung Medical Center
      • Hamburg, Tyskland, 20246
        • Rekruttering
        • Universitätsklinikum Hamburg-Eppendorf Onkologisches Zentrum Medizinische Klinik II
      • Leipzig, Tyskland, 04103
        • Rekruttering
        • Universitätsklinikum Leipzig - Klinik und Poliklinik für Hämatologie

Deltakelseskriterier

Forskere ser etter personer som passer til en bestemt beskrivelse, kalt kvalifikasjonskriterier. Noen eksempler på disse kriteriene er en persons generelle helsetilstand eller tidligere behandlinger.

Kvalifikasjonskriterier

Alder som er kvalifisert for studier

18 år og eldre (Voksen, Eldre voksen)

Tar imot friske frivillige

Nei

Kjønn som er kvalifisert for studier

Alle

Beskrivelse

Inclusion Criteria:

  • Diagnosed with MM per International Myeloma Working Group (IMWG) criteria
  • Eastern Cooperative Oncology Group Performance Status of 0, or 1, or 2
  • Resolution of AEs from prior anti-cancer therapy to Grade <=1
  • Agreement to undergo scheduled assessments and procedures

Additional Inclusion Criteria for SS2:

  • Completion of planned induction therapy and achievement of at least a partial response (PR)
  • Autologous Stem Cell Transplant (SCT) within 100 days prior to first study treatment and the absence of progressive disease
  • Cytogenetic high-risk features at diagnosis
  • Treatment with any investigational medicinal products, systemic cancer therapies, immunotherapies received previously in CO43923 (any arms) within 5 half-lives or 3 weeks whichever is the shortest
  • Agreement to comply with all local requirements of the lenalidomide risk minimization plan, which includes the global pregnancy prevention program
  • For female participants of childbearing potential: agreement to remain abstinent (refrain from heterosexual intercourse) or use contraception
  • For male participants: agreement to remain abstinent (refrain from heterosexual intercourse) or use a condom even if they have had a prior vasectomy, and agreement to refrain from donating sperm

Additional Inclusion Criteria for SS4:

  • Previously exposed to at least a PI, an IMiD, and an anti-CD38 antibody for the treatment of R/R MM for whom no suitable SOC therapy options are available

Exclusion Criteria:

  • Inability to comply with protocol-mandated hospitalization and procedures
  • History of confirmed progressive multifocal leukoencephalopathy
  • History of other malignancy within 2 years prior to screening
  • Current or past history of central nervous system (CNS) disease
  • Significant cardiovascular disease that may limit a participant's ability to adequately respond to a CRS event
  • Symptomatic active pulmonary disease or requiring supplemental oxygen
  • Known active bacterial, viral, fungal, mycobacterial, parasitic, or other infection at study enrollment, or any major episode of infection requiring treatment with IV antibiotics where the last dose of IV antibiotics was given within 14 days prior to first study treatment
  • Known or suspected chronic active Epstein-Barr virus (EBV) infection
  • Positive serologic or PCR test results for acute or chronic hepatitis B virus (HBV) infection
  • Acute or chronic hepatitis C virus (HCV) infection
  • Known history of HIV seropositivity
  • Administration of a live, attenuated vaccine within 4 weeks prior to initiation of study treatment or anticipation that such a live, attenuated vaccine will be required during the study
  • Any medical condition or abnormality in clinical laboratory tests that, in the investigator's judgment, precludes the participant's safe participation in and completion of the study, or which could affect compliance with the protocol or interpretation of results

Additional Exclusion Criteria for SS2:

  • Hypersensitivity reactions to lenalidomide or other immunomodulatory drugs
  • Harbor lesions at proximity of vital organs that may develop sudden decompensation/deterioration in the setting of a tumor flare
  • Prior treatment with any investigational medicinal product, systemic cancer therapy, or immunotherapies in any arm of study CO43923 within 5 half-lives or 3 weeks, whichever is shorter
  • Known active bacterial, viral, fungal, mycobacterial, parasitic, or other infection (excluding fungal infections of nail beds) at study enrollment, or any major episode of infection requiring treatment with IV antimicrobials where the last dose of IV antimicrobial was given within 14 days prior to first study treatment
  • History of erythema multiforme, Grade >=3 rash, or blistering following prior treatment with immunomodulatory derivatives
  • Pregnant or breastfeeding, or intending to become pregnant during the study or within 5 months after the final dose of study treatment Exlcusion Criteria Applicable to SS2 and SS4
  • History of autoimmune disease
  • Known history of hemophagocytic lymphohistiocytosis (HLH) or macrophage activation syndrome (MAS)
  • History of severe allergic or anaphylactic reactions to monoclonal antibody therapy (or recombinant antibody-related fusion proteins)
  • Received a cumulative dose of corticosteroids equivalent to >=140 mg of prednisone within the 14-day period before the first dose of the study drug (does not include pretreatment medication)
  • Active symptomatic COVID-19 infection at study enrollment or requiring treatment with IV antiviral where the last dose of IV antiviral treatment was given within 14 days prior to first study treatment. Participants with active COVID-19 infection must have clinical recovery and two negative antigen tests at least 24 hours apart prior to first study treatment.
  • Positive and quantifiable EBV PCR or CMV PCR prior to first study treatment

Additional Exclusion Criteria for SS4:

  • Treatment with any investigational medicinal products, systemic cancer therapies, immunotherapies within 5 half-lives or 12 weeks before starting pre-phase
  • History of anaphylaxis or hypersensitivity, including >=Grade 3 rash, during prior treatment with IMiDs, dexamethasone, any CELMoDs, or the excipients contained in the formulations
  • Known anaphylaxis, allergies, hypersensitivity, or intolerance to boron or mannitol, hyaluronidase, sorbitol, corticosteroids, monoclonal antibodies (or recombinant antibody-related fusion proteins), or human proteins, CRBN modulating agents or their excipients, or known sensitivity to mammalian-derived products
  • Administration of strong CYP3A modulators; administration of proton-pump inhibitors within 2 weeks of starting study treatment
  • Uncontrolled hypertension or uncontrolled diabetes within 14 days prior to enrollment
  • Concurrent administration of a strong inhibitor, modulator or inducer of cytochrome P450 (CYP3A4/5) (including within 14 days of initiating study treatment)
  • History of malignancies, other than MM, unless the subject has been free of the disease for >=5 years
  • Peripheral neuropathy >Grade 2
  • Prior treatment with cevostamab or another agent targeting FcRH5 or iberdomide
  • Pregnant or breastfeeding, or intending to become pregnant during the study or within 5 months after the final dose of study treatment
  • History of Stevens-Johnson syndrome, toxic epidermal necrolysis, or drug rash with eosinophilia and systemic symptoms
  • Treatment with systemic immunosuppressive medications
  • Prior treatment with CAR T-cell therapy (autologous or allogeneic) within 12 weeks before starting pre-phase
  • Autologous SCT within 100 days prior to starting pre-phase
  • Prior allogeneic SCT
  • Plasmacytoma in proximity of vital organs that may develop sudden decompensation/deterioration in the setting of a tumor flare

Studieplan

Denne delen gir detaljer om studieplanen, inkludert hvordan studien er utformet og hva studien måler.

Hvordan er studiet utformet?

Designdetaljer

  • Primært formål: Behandling
  • Tildeling: Randomisert
  • Intervensjonsmodell: Sekvensiell tildeling
  • Masking: Ingen (Open Label)

Våpen og intervensjoner

Deltakergruppe / Arm
Intervensjon / Behandling
Eksperimentell: Substudy 2: Dose Escalation and Expansion

In the pre-phase, participants will receive 2 step-up doses and a target dose of cevostamab. The step-up dose will be given on Day(D)1 and D4. The target dose will be given on D8. Subsequently the target dose will be administered on D1 and D15 for cycles 1-6 and D1 of cycle 7 onwards. Each cycle is 28 days. Lenalidomide will be administered by mouth (PO) on a 28-day cycle.

During the dose expansion phase, cevostamab will be administered following the same dosing schedule as the dose escalation phase. The target dose will be determined after the escalation phase. Lenalidomide will be administered PO on a 28-day cycle.

Enrollment for Substudy 2 has closed.

Substudy 2: Cevostamab will be administered intravenously (IV) on a 28-day cycle, up to a total of 13 cycles.

Substudy 4: Cevostamab will be administered by IV on a 21-day cycle, up to a total of 17 cycles.

Lenalidomide will be administered PO on days 1-21 of a 28-day cycle.

Tocilizumab will be administered for the treatment of cytokine release syndrome (CRS) when necessary.

Eksperimentell: Substudy 4: Dose Escalation and Expansion

In the pre-phase, participants will receive 2 step-up doses and a target dose of cevostamab. The step-up dose will be given on D1 and D4. The target dose will be given on D8. Subsequently the target dose will be administered on D1 of each cycle, every 3 weeks (Q3W). Each cycle is 21 days. Iberdomide will be administered PO on a 21-day cycle.

During the dose expansion phase, cevostamab will be administered following the same dosing schedule as the dose escalation phase. The target dose will be determined after the escalation phase. Iberdomide will be administered PO on a 21-day cycle.

Substudy 2: Cevostamab will be administered intravenously (IV) on a 28-day cycle, up to a total of 13 cycles.

Substudy 4: Cevostamab will be administered by IV on a 21-day cycle, up to a total of 17 cycles.

Tocilizumab will be administered for the treatment of cytokine release syndrome (CRS) when necessary.

Iberdomide will be administered PO on days 1-14 of a 21-day cycle.

Dexamethasone will be administered on Days 2 and 8 of Cycles 1-3.

Hva måler studien?

Primære resultatmål

Resultatmål
Tidsramme
Trinn 1: Prosentandel av deltakere med uønskede hendelser (AE)
Tidsramme: Baseline opptil ca. 5 år
Baseline opptil ca. 5 år
Trinn 2: Objektiv responsrate (ORR)
Tidsramme: Baseline opptil ca. 5 år
Baseline opptil ca. 5 år
Trinn 2: Complete Response (CR) eller Stringent Complete Response (sCR) rate
Tidsramme: Baseline opptil ca. 5 år
Baseline opptil ca. 5 år
Trinn 2: Rate of very good partial response (VGPR) eller bedre
Tidsramme: Baseline opptil ca. 5 år
Baseline opptil ca. 5 år
Trinn 2: Progresjonsfri overlevelse (PFS)
Tidsramme: Baseline opptil ca. 5 år
Baseline opptil ca. 5 år
Trinn 2: Total overlevelse (OS)
Tidsramme: Baseline opptil ca. 5 år
Baseline opptil ca. 5 år

Sekundære resultatmål

Resultatmål
Tidsramme
Trinn 1: Konvertering til en bedre respons
Tidsramme: Baseline opptil ca. 5 år
Baseline opptil ca. 5 år
Trinn 1: PFS
Tidsramme: Baseline opptil ca. 5 år
Baseline opptil ca. 5 år
Trinn 1 og 2: Varighet av respons (DOR)
Tidsramme: Baseline opptil ca. 5 år
Baseline opptil ca. 5 år
Trinn 1: OS
Tidsramme: Baseline opptil ca. 5 år
Baseline opptil ca. 5 år
Trinn 1 og 2: Minimal Residual Disease (MRD) Negativitetsrate
Tidsramme: Baseline opptil ca. 5 år
Baseline opptil ca. 5 år
Trinn 1: ORR
Tidsramme: Baseline opptil ca. 5 år
Baseline opptil ca. 5 år
Trinn 1: CR eller sCR Rate
Tidsramme: Baseline opptil ca. 5 år
Baseline opptil ca. 5 år
Trinn 1: Pris for VGPR eller bedre
Tidsramme: Baseline opptil ca. 5 år
Baseline opptil ca. 5 år
Trinn 2: Trinn 1: Prosentandel av deltakere med AE
Tidsramme: Baseline opptil ca. 5 år
Baseline opptil ca. 5 år
Trinn 1 og 2: Tid til første respons (for deltakere som oppnår en respons på PR eller bedre)
Tidsramme: Baseline opptil ca. 5 år
Baseline opptil ca. 5 år
Trinn 1 og 2: Tid til beste respons (for deltakere som oppnår en respons på PR eller bedre)
Tidsramme: Baseline opptil ca. 5 år
Baseline opptil ca. 5 år
Trinn 1 og 2: Maksimal konsentrasjon observert (Cmax)
Tidsramme: Baseline opptil ca. 5 år
Baseline opptil ca. 5 år
Trinn 1 og 2: Minimum konsentrasjon under steady-state forhold innenfor et doseringsintervall (Cmin)
Tidsramme: Baseline opptil ca. 5 år
Baseline opptil ca. 5 år
Trinn 1 og 2: Tid til maksimal konsentrasjon (Tmax)
Tidsramme: Baseline opptil ca. 5 år
Baseline opptil ca. 5 år
Trinn 1 og 2: Areal under konsentrasjon-tidskurven (AUC)
Tidsramme: Baseline opptil ca. 5 år
Baseline opptil ca. 5 år
Trinn 1 og 2: Total clearance of drug (CL)
Tidsramme: Baseline opptil ca. 5 år
Baseline opptil ca. 5 år
Trinn 1 og 2: Distribusjonsvolum ved stabil tilstand
Tidsramme: Baseline opptil ca. 5 år
Baseline opptil ca. 5 år
Trinn 1 og 2: Terminal halveringstid
Tidsramme: Baseline opptil ca. 5 år
Baseline opptil ca. 5 år

Samarbeidspartnere og etterforskere

Det er her du vil finne personer og organisasjoner som er involvert i denne studien.

Etterforskere

  • Studieleder: Clinical Trials, Hoffmann-La Roche

Publikasjoner og nyttige lenker

Den som er ansvarlig for å legge inn informasjon om studien leverer frivillig disse publikasjonene. Disse kan handle om alt relatert til studiet.

Studierekorddatoer

Disse datoene sporer fremdriften for innsending av studieposter og sammendragsresultater til ClinicalTrials.gov. Studieposter og rapporterte resultater gjennomgås av National Library of Medicine (NLM) for å sikre at de oppfyller spesifikke kvalitetskontrollstandarder før de legges ut på det offentlige nettstedet.

Studer hoveddatoer

Studiestart (Faktiske)

14. november 2023

Primær fullføring (Antatt)

31. juli 2028

Studiet fullført (Antatt)

31. juli 2028

Datoer for studieregistrering

Først innsendt

14. oktober 2022

Først innsendt som oppfylte QC-kriteriene

14. oktober 2022

Først lagt ut (Faktiske)

18. oktober 2022

Oppdateringer av studieposter

Sist oppdatering lagt ut (Faktiske)

5. november 2026

Siste oppdatering sendt inn som oppfylte QC-kriteriene

4. november 2026

Sist bekreftet

1. november 2026

Mer informasjon

Begreper knyttet til denne studien

Plan for individuelle deltakerdata (IPD)

Planlegger du å dele individuelle deltakerdata (IPD)?

JA

IPD-planbeskrivelse

For eligible studies, qualified researchers may request access to individual patient level clinical data. See Roche's commitment to transparency of clinical study information here: https://go.roche.com/data_sharing

Legemiddel- og utstyrsinformasjon, studiedokumenter

Studerer et amerikansk FDA-regulert medikamentprodukt

Ja

Studerer et amerikansk FDA-regulert enhetsprodukt

Nei

Denne informasjonen ble hentet direkte fra nettstedet clinicaltrials.gov uten noen endringer. Hvis du har noen forespørsler om å endre, fjerne eller oppdatere studiedetaljene dine, vennligst kontakt register@clinicaltrials.gov. Så snart en endring er implementert på clinicaltrials.gov, vil denne også bli oppdatert automatisk på nettstedet vårt. .

Abonnere